10-Q: Orgenesis Inc. Reports Q2 2024 Results, Faces Nasdaq Delisting Concerns

Orgenesis Inc. reported its financial results for the second quarter of 2024, highlighting a revenue increase but also ongoing challenges with profitability and Nasdaq compliance.

Summary

• Orgenesis Inc. reported a revenue of $246 thousand for the three months ended June 30, 2024, an increase from $113 thousand in the same period of 2023.
• The company's cost of revenues decreased significantly to $538 thousand from $3,232 thousand year-over-year.
• Operating loss for the quarter was $4,250 thousand, compared to $25,070 thousand in the prior year.
• Net loss for the quarter was $9,366 thousand, compared to $31,193 thousand in the same period last year.
• For the six months ended June 30, 2024, revenues were $387 thousand, up from $255 thousand in 2023.
• The company's net loss for the six months was $19,371 thousand, compared to $54,570 thousand in the prior year.
• The company has an accumulated deficit of $195,291 thousand and negative operating cash flows of $10,348 thousand for the six months ended June 30, 2024.
• Orgenesis is facing potential delisting from the Nasdaq Capital Market due to non-compliance with bid price and equity rules, with a deadline of October 14, 2024, to regain compliance.
• The company reconsolidated Octomera LLC into its accounts on January 29, 2024, after previously deconsolidating it in June 2023.
• Orgenesis entered into debt exchange agreements, converting $16,007 thousand of debt into equity.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive revenue growth but significant financial challenges, including going concern issues and potential delisting. The overall sentiment is negative due to the company's precarious financial situation.

Positives

• The company experienced a significant increase in revenue for both the three and six month periods ending June 30, 2024.
• Cost of revenues decreased substantially, indicating improved efficiency or reduced expenses.
• Selling, general, and administrative expenses saw a large decrease, suggesting cost-cutting measures are taking effect.
• The reconsolidation of Octomera LLC could lead to strategic advantages and operational synergies.
• The debt exchange agreements reduced the company's debt burden and improved its capital structure.
• The sale of OMPULs to Germfree generated a significant cash inflow.

Negatives

• The company continues to report significant net losses for both the three and six month periods ending June 30, 2024.
• The company has a substantial accumulated deficit and negative operating cash flows, raising concerns about its financial sustainability.
• The company is facing potential delisting from Nasdaq due to non-compliance with listing rules.
• The deconsolidation of Orgenesis Biotech Israel Limited (OBI) resulted in a loss of $66 thousand.
• The company's working capital is significantly negative, indicating potential liquidity issues.
• The company's auditors have identified a material weakness in internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is in doubt due to its financial condition.
• There is a risk of delisting from the Nasdaq Capital Market if the company fails to regain compliance with listing requirements by October 14, 2024.
• The company may not be able to raise additional capital on acceptable terms, or at all, which could force it to curtail operations or file for bankruptcy.
• The company's operations in Israel may be affected by ongoing geopolitical and military conditions.
• The company's reliance on external funding sources makes it vulnerable to market conditions and investor sentiment.
• The company's internal control over financial reporting has a material weakness, which could lead to errors in financial reporting.

Future Outlook

The company plans to raise additional capital to continue operations, repay outstanding loans, increase revenues, and reduce expenditures. There is no assurance that the company will be able to raise additional capital on acceptable terms, or at all.

Management Comments

• Management has assessed the company's financial condition and concluded that there is substantial doubt about its ability to continue as a going concern.
• Management is planning to raise additional capital to continue operations and repay outstanding loans.
• Management is exploring additional avenues to increase revenues and reduce or delay expenditures.

Industry Context

The company operates in the biotech industry, specifically focusing on cell and gene therapies. The document highlights the challenges of scaling and commercializing these therapies, which is a common issue in the industry. The company's point-of-care approach is an attempt to address these challenges.

Comparison to Industry Standards

• The company's revenue growth is positive, but its continued losses are concerning compared to industry benchmarks for commercial-stage biotech companies.
• The company's negative working capital and going concern issues are not typical for established biotech firms, indicating significant financial distress.
• The company's reliance on external funding and its struggle to meet Nasdaq listing requirements are not common among well-capitalized biotech companies.
• The company's focus on point-of-care manufacturing is a differentiating factor, but its financial performance needs to improve to validate this approach.
• Compared to companies like Kite Pharma or Novartis, which have successfully commercialized cell therapies, Orgenesis is still in an early stage of development and faces significant financial hurdles.

Legal Proceedings

• The company is involved in several legal proceedings, including a claim for royalties, a claim for finders fees, and a claim for payment of a convertible loan.
• The company is also involved in a legal proceeding related to a lease agreement.

Stakeholder Impact

• Shareholders face the risk of significant dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost-cutting measures or operational changes.
• Customers may be impacted by the company's financial instability and potential disruptions to services.
• Creditors face the risk of non-payment if the company's financial situation does not improve.
• Suppliers may be affected by potential delays or changes in payment terms.

Next Steps

• The company needs to regain compliance with Nasdaq listing rules by October 14, 2024.
• The company plans to raise additional capital to continue operations and repay outstanding loans.
• The company will explore additional avenues to increase revenues and reduce or delay expenditures.

Key Dates

Keywords

Orgenesis, Cell and Gene Therapies, POCare, Nasdaq, Financial Results, Debt Exchange, Octomera, Delisting, Going Concern, OMPULs